New ways to improve treatments for dementia and cognitive decline
Official title: Novel Methods for Clinical Trials in Dementia and Cognitive Decline
Funded at University of Texas Hlth Science Center · NIH-10837906 · Data updated 2026-11-12
This study is looking at how certain proteins from fat might affect how well the medication donepezil works for people with dementia, and it aims to find out which patients could benefit the most from this treatment, all while making it easy and safe for participants to join, especially those who aren't vaccinated against COVID-19.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | May 15, 2023 |
| Project end | April 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $455,996 |
| NIH project number | 5R01AG080548-02 |
| Project ID | NIH-10837906 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults experiencing cognitive decline or diagnosed with dementia, particularly those who may benefit from donepezil treatment.
✕Less likely to help
Patients with non-dementia-related cognitive issues or those who are not eligible for donepezil treatment may not receive benefits from this research.
What this research studies
This research investigates how certain proteins released by fat tissues, known as adipokines, may influence the effectiveness of the FDA-approved medication donepezil in treating dementia. The study will involve a clinical trial where participants may be assessed through telephone interviews to ensure safety and convenience, especially for those unvaccinated against COVID-19. By using innovative algorithms, the research aims to identify which patients are most likely to benefit from the treatment, potentially leading to more personalized care for individuals with dementia. The goal is to enhance the design and execution of future dementia-related clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for dementia, enhancing cognitive function and quality of life for patients.
How similar studies have gone: Previous research has shown promise in using biomarkers and innovative assessment methods in dementia treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Royall, Donald R — University of Texas Hlth Science Center
- Study coordinator: Royall, Donald R
Related research
Other NIH-funded projects on the same topics.
-
Cash transfers in South Africa to reduce dementia risk in later life
This project tests whether government cash transfers in rural South Africa help protect people’s thinking and memory as they age.
-
Dynamic cognitive health from everyday online surveys in dementia research
A big study uses everyday online surveys to read how people’s thinking changes over time, with the goal of spotting early signs of dementia.
-
Longitudinal multi-omics map of cognitive decline and dementia
A long-term study at University of Washington uses blood and brain data over many years to identify biological markers linked to cognitive decline and Alzheimer’s dementia, with the goal of finding new treatment targets.
-
Peripheral immune signals and blood vessel health in aging and dementia
This project looks at how platelet and neutrophil activity relate to brain changes and biomarkers of Alzheimer’s disease in older adults, especially those at higher cardiovascular risk.
-
Understanding cognitive decline and Alzheimer’s changes in people with long‑duration type 1 diabetes
A long-term study in adults with type 1 diabetes investigates why some people experience memory and thinking difficulties and brain changes typical of Alzheimer's disease.
-
Cash transfers in South Africa linked to later-life memory and dementia risk
A researchers’ team is testing whether government cash transfers in rural South Africa can help protect older adults from memory decline and dementia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.